ClinicalTrials.gg
Active, not recruitingNCT03859128JUPITER 04Updated Aug 10, 2026

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection

A Phase 2/3 interventional study of TORIPALIMAB INJECTION(JS001 ) in Hepatocellular Carcinoma, sponsored by Shanghai Junshi Bioscience Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Shanghai Junshi Bioscience Co., Ltd. · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
427
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing toripalimab in Carcinoma, Hepatocellular — 2 open to participants now, 5 under way, 3 of them phase 3. toripalimab · Carcinoma, Hepatocellular.

Enrollment
2nd of 21
427 · median 46
Started
2019
with 8 others
Phase 2/3
Only one
of the 21
Registered
1st of 21
by date
Lead sponsor
5 of 21
Shanghai Junshi Bioscience Co., Ltd.

Among the 21 studies testing toripalimab in Carcinoma, Hepatocellular, this one is the 2nd largest by enrollment, is one of 9 that started in 2019, is the only one in phase 2/3, and was the 1st registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

2 of the 21 studies testing toripalimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing toripalimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This study will investigate if Toripalimab (A PD-1 Inhibitor) will improve recurrence-free survival (RFS) compared to placebo in participants with HCC and are at high risk of recurrence after complete resection with no residual of tumour.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. HCC with at least one protocol defined risk factor, diagnosed confirmed by central pathological review and received R0 resection;
  2. BICR confirmed no resdual tumor lesions are detected in liver;
  3. Child-Puch score, Class A;
  4. score is 0;

Exclusion criteria

Exclusion Criteria:

  1. Patients previously received antibody, PD-L1 antibody, PD-L2 antibody or CTLA-4 antibodies, including those who have participated in the JS001 clinical study;
  2. Portal vein tumor thrombi or liver or recurrent liver cancer;
  3. With symptoms of central nervous system metastasis;
  4. With any history of active disease or autoimmune disease;
  5. Known liver diseases with clinical significance;
  6. Patients infected by virus (HBV), virus (HCV), hepatitis D virus (HDV):

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
427 participants (actual)

Study arms

  • Active comparator
    Group A

    TORIPALIMAB 240mg ,Q3W, up to 16 cycles

    Biological: TORIPALIMAB INJECTION(JS001 )

  • Placebo comparator
    Group B

    Placebo 240mg Q3W, up to 16 cycles

    Biological: TORIPALIMAB INJECTION(JS001 )

Interventions

  • BiologicalToripalimabStudies of ToripalimabToripalimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Arm A: Toripalimab 240mg IV(Injection of Vein) Q3W Arm B: Placebo 240mg IV(Injection of Vein) Q3W

06

What researchers measure

Primary outcomes

  1. BICR-RFS

    Defined as the time from randomization to the first documented disease recurrence or death.

    Time frame: Time frame is up to 100 months (for interim analysis, up to 92 months for Primary analysis)

Secondary outcomes

  1. Investigator-RFS

    the time from randomization to the date of the first documented progressive disease (tumor evlauation by BICR in accordance with RECIST 1.1), or to the date of death for any cause, whichever occurs first

    Time frame: up to 100 months

  2. 12-month recurrence-free survival rate (RFS12)

    probability of patients without recurrence or death for any cause at Month 12

    Time frame: up to 100 months

  3. 24-month recurrence-free survival rate (RFS24)

    probability of patients without recurrence or death for any cause at Month 24

    Time frame: up to 100 months

  4. Time to recurrence (TTR)

    the time from randomization to the first documented disease recurrence

    Time frame: up to 44 months

  5. Time to local recurrence (TTLR)

    the time from randomization to the first documented local disease recurrence

    Time frame: up to 44 months

  6. Overall survival (OS)

    the time from randomization to death for any cause

    Time frame: up to 44 months

  7. 12- and 24-month overall survival rate (OS12 and OS24)

    probability of patients surviving at Month 12 and 24, respectively

    Time frame: up to 44 months

  8. Incidence of AEs

    Incidence of AEs (including SAEs and AESIs) is evaluated by the investigator, and severity is determined in accordance with CTCAE v5.0

    Time frame: up to 44 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2019 (actual). Primary completion is estimated for Dec 2026, 93 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2019
First posted
Mar 1, 2019
StartActual
Mar 5, 2019
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03859128
Responsible party
Sponsor
First posted
Mar 1, 2019
Start date
Mar 5, 2019
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Toripalimab

Start the discussion